1. AstraZeneca gets FDA OK for Imfinzi in small-cell lung cancer— Regeneron and Sanofi treat first person outside US in coronavirus drug trial — FDA accepts Roche's NDA for Xofluza to treat flu in children — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Allergan's Botox still a physician favorite for migraine despite CGRP push: analyst

Discussion in 'Pharma/Biotech Companies - In the News' started by cafead, Feb 21, 2020 at 11:22 AM.

  1. cafead

    cafead Administrator
    Staff Member

    Nov 21, 2001
    Likes Received:
    via With CGRP drugs on the rise in the preventive migraine market, old stalwarts like Allergan's Botox are feeling the pinch from the new competition. But a new survey says neurologists may not be so quick to give up on Botox––and that could be another win for AbbVie on the eve of its Allergan merger.

    article source